Pakistan’s leading pharmaceutical company declares a partnership with hospitALL to initiate a Virtual Counseling Platform linking Physician and Patient.
ClinicALL, the IT platform aims to provide a solution for the ongoing coronavirus pandemic that has resulted in many lives being lost due to a lack of vaccination available.
Ferozsons Laboratories Limited, through its subsidiary BF Biosciences Limited, has produced remdesivir injections, under the brand name Remidia, under license and technology transfer from Gilead Sciences, the company that receives USFDA emergency use authorization for the treatment of Covid-19 patients.
“The partnership between a pharmaceutical and technology company is a transformative step towards digitising healthcare infrastructure of the country,” stated Mr Ayub Ghauri, Chief Executive Officer, HospitALL.
This solution is specifically designed to keep the convenience and confidentiality of patients and healthcare professionals as a priority. Doctors will be able to communicate with patients in real-time through video conferencing, while patients will be able to take electronic.